TL;DR: A January 2026 peer-reviewed study from McGill University found that gamma irradiation reduces fungal CFU counts in cannabis but does not eliminate mycotoxigenic fungi, their biosynthetic DNA, or residual mycotoxins. Irradiated cannabis passed Canada's regulatory CFU threshold while still harboring viable spores of Aspergillus, Penicillium, and Fusarium. For processors depending on irradiation as their decontamination method, this creates an exposure they may not know exists—and one that current ELISA-based testing may not detect.
Key Takeaways
- The McGill study found viable mycotoxigenic fungal spores, DNA fragments, and aflatoxin/ochratoxin residues in cannabis that passed CFU-based regulatory testing after irradiation
- ELISA, the standard mycotoxin detection method, was not sensitive enough to detect trace amounts left after irradiation without supplemental molecular techniques
- X-ray and gamma irradiation work by damaging microbial DNA—but that mechanism does not destroy pre-formed mycotoxins already present in the product
- Vaporized hydrogen peroxide (VHP) operates through oxidative chemistry rather than DNA damage—a fundamentally different mechanism with implications for mycotoxin mitigation
- FDA's January 2024 designation of VHP as an Established Category A sterilization method places it in the same regulatory tier as gamma radiation, steam, and ethylene oxide—but with a cleaner residue and toxin profile
The Study That Changed the Irradiation Calculus
On October 28, 2025, Toxins — a peer-reviewed journal published by MDPI — published a study by researchers at McGill University's Department of Food Science and Agricultural Chemistry: "Detection of Mycotoxigenic Fungi and Residual Mycotoxins in Cannabis Buds Following Gamma Irradiation."
The findings were reported publicly by McGill's newsroom on January 15, 2026.
The researchers analyzed dried cannabis buds — both non-irradiated and irradiated samples from a licensed producer, plus retail products from the Société Québécoise du Cannabis (SQDC). They applied three complementary detection methods:
- Culture-based assays to identify living fungi and bacteria
- PCR/qPCR to detect fungal DNA even when viable organisms could not be cultured
- ELISA assays to measure mycotoxins including aflatoxins and ochratoxins
The headline finding: all irradiated cannabis samples complied with Health Canada's regulatory threshold of 50,000 CFU/g — the standard CFU-based test used for compliance. But when the researchers applied PCR and culture-based methods in parallel, they found viable spores of Aspergillus, Penicillium, and Fusarium still present. Mycotoxin residues — the actual toxic compounds these fungi produce — also persisted.
The product passed the regulatory test. The hazard remained.
Why Irradiation Has This Limitation
Gamma irradiation and x-ray irradiation work by delivering ionizing energy to the microbial DNA inside the product. The energy disrupts chemical bonds in the DNA strand, preventing the microbe from reproducing. This mechanism is effective at reducing viable microbial counts — which is why irradiated product routinely passes CFU-based testing.
But this mechanism has two structural limitations that the McGill study exposed:
1. It Cannot Destroy Pre-Formed Mycotoxins
Mycotoxins are secondary metabolites — chemical compounds produced by fungi, not the fungi themselves. Aflatoxins (produced by Aspergillus flavus and Aspergillus parasiticus) and ochratoxin A (produced by Aspergillus ochraceus and various Penicillium species) are small, heat-stable, chemically resilient molecules. They are not alive. Damaging fungal DNA has no effect on toxin molecules that were already synthesized and deposited in the product before irradiation.
This is not a failure of irradiation equipment or dose delivery. It is a chemical reality. Any decontamination method that works by killing organisms — rather than oxidizing or destroying organic compounds — will share this limitation with pre-formed toxins.
2. Spore Persistence at Regulatory-Compliant CFU Levels
The study found viable spores of mycotoxigenic species remained even after irradiation reduced total CFU counts below the regulatory threshold. Aspergillus spores are particularly radiation-resistant, a characteristic documented in multiple prior studies the McGill team cites. A single surviving spore capable of germination post-processing represents a re-contamination vector — particularly if the product is stored at elevated humidity before or after testing.
As the McGill researchers noted: "A single spore can cause disease." For immunocompromised patients — cancer patients, transplant recipients, individuals with HIV/AIDS — who represent a substantial portion of medicinal cannabis users, this is not an abstract concern.
The Detection Gap: Why ELISA May Not Catch It
The study's finding about testing methodology is nearly as significant as its finding about irradiation.
ELISA (enzyme-linked immunosorbent assay) is the current industry standard for mycotoxin detection in cannabis. It is fast, scalable, and widely adopted by commercial testing laboratories. The McGill researchers found that ELISA alone was not sensitive enough to detect the trace levels of mycotoxins remaining after irradiation without supplemental molecular techniques.
This means the problem compounds on itself: irradiation reduces but does not eliminate mycotoxins; the standard detection method is not sensitive enough to find the residual amount that remains. A product can pass both the microbial CFU test and the ELISA mycotoxin screen and still contain detectable mycotoxin residues when more sensitive methods are applied.
For processors, this matters in two directions. First, it suggests that your current test pass does not guarantee the absence of mycotoxin risk if your decontamination method is irradiation-based. Second, as testing standards evolve — and the study specifically calls for stricter standards — the detection methods used in compliance testing are likely to become more sensitive. Products that pass today's tests may not pass tomorrow's.
How the Irradiation Market Is Positioned
The irradiation-based decontamination segment in cannabis has grown substantially over the past several years. Major providers include XRpure (XR16 and XR12 x-ray systems), Rad Source Technologies (RS 420 Series with Quastar Photonic technology), and several others.
These systems are marketed on their ability to achieve 3-log or greater microbial reduction — meaning a 99.9% reduction in viable microbial counts — without degrading cannabinoids, terpenes, or moisture content. These claims are not contested here; irradiation does effectively reduce viable CFU counts.
The McGill study does not invalidate the CFU-reduction performance of irradiation. It identifies a category of risk — mycotoxin residues and mycotoxigenic spore persistence — that CFU reduction does not address. That is a different question from whether irradiation reduces microbial counts, and the answer to both can be true simultaneously.
What the study changes is the confidence an operator can have that an irradiation pass is equivalent to a clean product, particularly for mycotoxigenic hazards.
VHP's Mechanism: Why It Approaches the Problem Differently
Vaporized hydrogen peroxide operates through oxidative chemistry rather than DNA damage. VHP molecules are highly reactive oxidizing agents — they react with organic compounds including proteins, lipids, and nucleic acids, disrupting cellular structure broadly rather than targeting DNA replication specifically.
This oxidative mechanism has implications for pre-formed mycotoxins. Where irradiation leaves stable toxin molecules intact, oxidative processes have demonstrated efficacy against aflatoxins and other mycotoxins in food and pharmaceutical decontamination contexts. The chemical reactivity of VHP engages organic compounds directly, not just living organisms.
On January 8, 2024, the FDA designated VHP as an Established Category A sterilization method — placing it alongside steam (moist heat), dry heat, ethylene oxide, and radiation. This designation reflects VHP's long history of safety and effectiveness and was accompanied by the FDA's recognition of ISO 22441:2022 as the governing consensus standard for VHP process validation.
The Category A designation matters for cannabis processors for a practical reason: it means VHP's validation framework is not proprietary or novel. Any cannabis processor implementing VHP can validate their process against a published, internationally recognized standard — the same standard used for pharmaceutical-grade sterilization — rather than building a custom protocol. That is the difference between a method an OLCC auditor can evaluate against a known benchmark and one they cannot.
The Regulatory Trajectory and What It Means for Processor Risk
The McGill team explicitly called for stricter testing standards in their conclusions. The study's findings on ELISA's limitations suggest that regulators and testing laboratories will, over time, add more sensitive molecular detection methods to their mycotoxin screening protocols.
In Oregon, mycotoxin failures cannot be remediated — destruction is mandatory. In practice, this means that a processor whose irradiated product passes today's tests but contains detectable mycotoxin residues under more sensitive methods faces the possibility of a future destruction order for product they believed was compliant.
That risk profile is distinct from the risk profile of a processor using an oxidative in-process control step. The distinction is not whether you are meeting today's testing threshold — both approaches can do that — but whether the decontamination mechanism you are using addresses the underlying contamination or only the visible metric regulators currently measure.
The study's conclusion is direct: "Cannabis products passing the standard CFU-based testing may still harbor microbial threats with clinical relevance. Since gamma irradiation is insufficient for eliminating toxigenic fungi, their biosynthetic genes, or residual mycotoxins... more comprehensive testing methods and/or additional safety measures are needed."
A Note on Scope
The McGill study focused on gamma irradiation. X-ray irradiation, which commercial systems like those from XRpure and Rad Source use, operates on the same fundamental mechanism — ionizing energy damages microbial DNA. The specific dose-response and spore survival characteristics may differ between gamma and x-ray sources, and no equivalent study has been published specifically on x-ray irradiation and mycotoxin persistence in cannabis as of this writing.
Processors evaluating irradiation-based systems should request data on mycotoxin residue testing — not only CFU reduction — from vendors before making a decontamination infrastructure decision. Vendor claims focused exclusively on CFU log-reduction do not speak to the mycotoxin question the McGill study raised.
Frequently Asked Questions
Does the McGill study mean irradiation is ineffective for cannabis decontamination?
Not for CFU reduction. Irradiation reliably reduces viable microbial counts and cannabis irradiated with appropriate doses routinely passes CFU-based compliance tests. The study identified a specific limitation: it does not eliminate pre-formed mycotoxins or all mycotoxigenic fungal spores. Whether that limitation is material to your operation depends on your product type, your target market, and what testing standards apply now and are likely to apply in the future.
Why can't irradiation destroy mycotoxins if it can kill the fungi that produce them?
Mycotoxins are stable chemical compounds, not living organisms. They are produced by fungi but exist independently of the fungal cell. The mechanism irradiation uses — disrupting DNA replication — has no effect on a molecule that does not replicate. Pre-formed mycotoxins require a chemical reaction to degrade, not a mechanism targeting biological reproduction.
Is VHP validated for cannabis specifically?
VHP has been validated in pharmaceutical and medical device decontamination contexts for decades. The FDA's January 2024 Category A designation and ISO 22441:2022 provide the validation framework. Oregon's OLCC explicitly recognizes sterilization processes — including VHP — as a compliant remediation method for microbial failures. Cannabis-specific performance validation using VHP has also been conducted; the Bioquell study documented total elimination of target organisms in cannabis environments with zero residue and no adverse effect on product quality.
What should a processor do with this information if they currently use irradiation?
The appropriate response is not to immediately change your decontamination approach but to request mycotoxin residue data from your vendor — not just CFU reduction data — and to evaluate whether your current testing protocol includes the molecular methods needed to detect trace mycotoxins post-irradiation. If it does not, you may want to supplement your testing and assess whether your decontamination method addresses the full scope of the compliance risk you carry.
Does this affect hemp processors as well as cannabis processors?
Yes. The same mycotoxigenic fungi (Aspergillus, Fusarium, Penicillium) contaminate hemp and cannabis crops under similar conditions. Hemp operators subject to federal compliance requirements or USDA testing standards face the same mycotoxin residue question if irradiation is part of their decontamination workflow.
Primary reference: Rani M, Kaddoura MJ, Samsatly J, Chamberland G, Jabaj S, George S. "Detection of Mycotoxigenic Fungi and Residual Mycotoxins in Cannabis Buds Following Gamma Irradiation." Toxins. 2025;17(11):528. doi:10.3390/toxins17110528. Newsroom coverage: McGill University, January 15, 2026.